drugset / Trial / NCT00819013

Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults

NCT00819013 ↗

Phase 1 Completed 87 enrolled Sanofi
RandomizedParallel-groupTriple-blindPrevention

Summary

This multi-center study will be conducted in the United States with up to 80 healthy adult subjects. Subjects will be scheduled to receive a total of two (2) injections with 1 injection each administered. Subjects will be randomized according to a randomization scheme.

Timeline

Start
2007-07
Primary completion
2009-01
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ACAM FLU-A Unknown 0.5 ml Intramuscular

Indications